The rapid pace ofg enomic science advancements,i ncludingthe completion ofthe humangenomesequence,the extensivec ataloguingof genetic variation andthe acceleration oftechnologiest oassess such variation,c ombined withc linicalp rogrammesw ithrich phenotypic data, serveasthe foundation for the designandexecution ofpharmacogenomic studieswhich haveanimpactonthe pharmaceuticalpipeline fromearly discovery through to the marketplace.The authors discuss the required infrastructureto supportp harmacogenomic studies andprovide insightinto the strategiesandpracticalapplication to influence decision makingi nt he pharmaceuticals etting.Further,the influence ofpharmacogenomicsiscurrently affectingpatient carei nt he oncologyarea andi shighlighted asevident impactint he marketplace.
Introduction
Pharmaceuticalengagement ofthe pharmacogenomicsdisciplineg ained significant momentum int he mid-1990s as colleaguesw ithint he industryr ecognised the potential opportunity for the emergingfi eldto havea nimpacto nv arious phaseso fthe drugd iscovery andd evelopment processes. Whilethe optimism ande xcitement for thisemergingd isciplinewashigh, the scientific andtechnologicalhurdlesrequired to deliverp harmacogenomicss eemed significant. Att he time, the demonstration ofpharmacogenomic impactasembodied byt he drugmetabolism fieldwasevident,yetm any hurdles remained to enablethe delivery ofc omprehensivepharmacogenomic studiest oexplored iseasestatea ndd rugresponse relationships. Thesehurdlesincluded acompletedraftsequence ofthe humangenome, not expected until2 005.Fromt his sequence wouldthenemerge the catalogueofhumangenome variation,andthiswasnot expected untilseveralyears afterthe completion ofthe humangenomesequence.Speculation atthe timesuggested thatm orethan3 00,000 evenly spaced, single nucleotide polymorphisms (SNPs) wouldb eneeded to performcomprehensivepharmacogenomic studies-ascale unimaginableatt he time.
1,2 How couldi tbe possibleto cataloguethe SNPsneeded to performwhole-genomeassociation studiesandc onductt he genotyping-the buildingb locks speculated to drivethe scientific revolution needed to fully deliverp harmacogenomics?
Overt he past teny ears,significant technological progress to enablepharmacogenomicshasbeenachieved.
The InternationalHumanGenomeprojectandC eleraraced to publishthe workingd raftgenomesequence in2 001 3,4 -four years ahead ofschedule, andthe SNPC onsortium, formed in1 999 through partnershipbetweent he academic andi ndustrialcommunity,d eveloped the firstcomprehensive SNP map,published inNovember2 000,a head ofschedule, belowcost ande xceedingthe initialgoalo fi dentifing 300,000SNPmarkers ofwhich 150,000w ouldb emapped bys ome1.12 M, delivering1.42Mmapped SNPsfor the scientific community atl arge to utilisef or scientific research. 5, 6 Thishasn ow evolved into the International HapMapp roject,which will furtherr efinethe SNPsr equired for comprehensivea ssociation analysisbyidentifyingc ritical patternso fS NPst hatcosegregatef romgeneration to generation int he formo fh aplotypetagsandmayp rovide the frameworkf romw hich humanw hole-genomea ssociation studiesared esigned. 7 Inparallelwiththe rapid advancementsinthe identification andmappingofS NPsacross the humangenome, technologicaldiscoveriesande nhancements to high-throughput genotypinghavealso madesignificant strides. Overt he course ofthe last fiveyears,leadingb iotech firmshaved rivengenotypingthroughput to scalesint he ordero fmillions perday whilesignificantly drivingdowncosts. Thesetechnologiesare nowavailableto humangeneticss cientists to supportl arge multi-genea ssociation studiesandthe early application of humanw hole-genomea ssociation studies.
So,whilei nt he mid-1990sm any peopleh eralded the revolution of'personalised medicine'and'the rightdrugf or the rightpatient',the realists understoodthat,likeany revolution,scientific research andtechnologicaladvancesw ouldb e required to shapethe potentialimportance ofthisfieldto modern medicine.Itisnow understoodthatany twoindividuals differfromeach otheratt he DNA sequence levelbya mere0.1 percent. Ye titisthis0.1 percent difference which makeseach person uniquea ndh oldst he keytodifferencesin diseasesusceptibility andprogression,aswell asour responseto therapeutic intervention. 8 Aso fnow,the foundation hasbeen laid for the broadeningapplication ofpharmacogenomics; clear examplesexist inm edicalp ractice,andscientific experiments cann ow commence atapace andlevelwhich wouldh ave seemed unimaginableback inthe mid-1990s.Furthermore, the face ofthe pharmaceuticalindustryhaschangedd ramatically; withe ver-increasingd evelopment costs andd ecreasingnumbers ofnewdruga pprovals,the challengesfacingthe industry haveneverbeenmoresignificant.Thispaperaims to highlight the infrastructureneeded to integratepharmacogenomicsinto the pharmaceuticalbusiness,aswell asstrategiesfor application, andd iscussesthe potentialapplications andopportunitiest hat thisfieldoffers to influence medicalcare.
Infrastructuref or delivering pharmacogenomicsinto the pharmaceuticals etting
The disciplineofpharmacogenomicsiscurrently beingapplied throughout the drugd iscovery andd evelopment process,a s depicted inFigure1. Highlights include: applyingh uman geneticst oensurethatt he best therapeutic targets areprioritised for discovery investment; the comprehensivee valuation ofthe targetgenesequence inm ultiplesubjects to determine the genetic heterogeneity present indifferent ethnic populations;t he useofg eneticst os electp articulars ubpopulations andinearly proofofconcept studies; and, finally,the potential to predictefficacyandsafety ofnewmedicinesmoreprecisely. Prior to the effectivei ntegration anda pplication ofpharmacogenomics,h owever,significant investment andi nfrastructurewasr equired to integratepharmacogenomicsinto these processes. Theseareasarehighlighted inFigure2anddiscussed inm ored etailbelow.
Appropriatei nformed consent
The ability to collectDNA, asw ell aso thert ypeso fg enomic samples,f roms tudys ubjects isdirectly dependent on patient informed consent ast ot he risksandb enefits associated with the samplec ollection.Aseparatei nformed consent,which statest he purposea ndthe useofthe samples,a ssurance of patient confidentiality through anonymisation or de-identification ofuniquepatient identifiers andc linicaldata, asw ell as the optionalparticipation inthisdonation,hasbeenanintegral part ofpatient acceptance int he clinicalt rials etting.Within current Pfizerclinicalp rogrammesitisn ot unusualfor patient consent for genomic samplec ollection to exceed 80p ercent inclinicals tudiest akingplace incountriesaround the world.
Collection ofphenotypic data
The ability to executea ny genetic studyr equiresaccurate andc omprehensivephenotypes,which atbest arequantitative andreliable, to enablerobust genetic analyses. Clinicalt rials servea sanexcellent startingpoint for genetic research aimed atbetteru nderstandingthe underlyingd iseasestatea ndprovidingc linicalr esults includingoutcomemeasuresand drugresponse, bothofwhich candrivepharmacogenomic investigations. Clinicalt rials arenot genetic studiesbydesign, however,a ndc riticalr eviewo fthe completed studyw ill oftenr equirec areful epidemiologicalevaluation to ensurethe appropriatestudydesign. Thiso fteninvolvesensuringthat thosesubjects donatingD NA samplesarereflectiveofthe entirestudypopulation andarenot biased inany way. If oneis interrogatingd rugresponsephenotypes,c aremust be taken to examinethe demographicsofthe responder/non-responder subgroups. Similarly,whens afety events arei nvestigated, subjects experiencingthe adversee vent must be closely matched to thosesubjects receivingthe drugandexhibitingno such adversee vent.
Whenconsideringthe useofc linicalt rials amplesfor diseaseg enei nterrogations,the ascertainment ofa ppropriately matched control populations to support such genetic studies isequally important. Often,c linicalm ethodologys tudiest o ascertaincontrol populationsmatched on demographicsaswell asoncertainclinicalphenotypespresent inthe casepopulation arerequired.Int he authors' studieso fosteoarthritis,c ritical carewast akent oexecuteastudyw hich identifiedc ontrol individuals whow ereradiographically free ofj oint space narrowing, to ensurea ccuratec ontrol phenotypestatus. 9 Thesec ollectionst henallowt he designande xecution of case-control association studiesins upporto fb othtargetv alidation andg enetic biomarkerdiscovery to support clinical development programmest argetingthe specific disease.
Te chnologyfor delivery ofg enetic analysis
The rapid pace oftechnologyadvancementsenablest he interrogation ofthe entiregenomeatthe levelofDNA, RNA or protein. Te chnologyhasm oved rapidly fromm ethodso f restriction fragment polymorphism (RFLP)s coringofg enetic variation to examiningi ndividualgenemarkers associated withvarious phenotypes, 10 to SNPscoringto examinemultiplemarkers inmultiplecandidategenes, 11 to nowhavingthe ability to interrogatethousandsofSNP markers usingmethods typified bySequenomm ass spec, 12 Illuminab ead-based methods, 13 the Affymetrixhigh-density SNP chips 14 and Perlegenhigh-density wafers. 15 Itisn ow possibleto examine hundredso fmillions ofS NPsw ithins everalw eeks,a st he authorsared oingthrough theircollaboration withP erlegen Sciencest os tudym etabolic syndromea ndd epression phenotypes. Itisanticipated thatw hole-genomesequencingi na timely andc ost-effectivemannerm ayr epresent the next technologicalfloodgate. 16 
Information technology
Oneofthe singlemost important challengesfacingthe field ofpharmacogenomicsr estsint he handso fthe information technologyexperts. Thevast amount ofc linicaldata, combined withgenomic data, requiresawell designed information architectureto enableh ypothesisgeneration ato nee ndof the portfolioandvalidated systems to enablethe useofthe information inr egulatorys ubmissionsatt he otherend.For example, onemust be ableto track clinicalgenomic samples fromthe patient fromsampleprocessingthrough to the sample repository,e nsuringthatt herei sintegrated information regardingi nformed consent andpotentialr estrictions on
Figure1. Applyingpharmacogenomicst odelivernewmedicines. The ability to integratepharmacogenomicsinto the drugdiscovery andd evelopment process isac ontinuum witha pplications ateach stepo fthe process. Thisdiagramhighlights the various phaseso f pharmaceuticalapplication which areh ighlighted inthisp aper.
Figure2. Infrastructurerequirements for pharmacogenomics. Much investment invarious tools andtechnologiesarerequired to ensurethe seamless integration ofpharmacogenomicsinto the pharmaceuticals ettingto deliverv alueandi mpactthroughout the pipeline.
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Review PERSPECTIVE sampleuse, andthatclinicaldataa ssociated withthe matched genomic samplei sentered into ad atabase.Moreover,often,a finals tepo fa nonymisation or de-identification must occur prior to initiation ofapharmacogenomic study. Att hiss tage, the challenge liesint he ability to effectively query the clinical datai no rdert odevelop specific hypothesest hatcanbe addressed byp harmacogenomic investigations,f ollowed by datasystems thatw ill thenhousea ll ofthe newly generated genomic data, oftenderived fromv ery different typeso f analysisp latforms.
The ability to effectively integratethesed atawithc linical dataandto minesuch datasets remains elusive, andwill require acomprehensiveinformation technologysolution to maximise the utility ofresearch studies. Thiss ophisticated knowledge baseb ecomesaprimary limitation inm any cases,a st he ability to integratea nde ffectively mined isparated atasources remains challengingandtimeintensive;however,thiswill have to be addressed ins ophisticated systems to enablemaximum returno ninvestmentsinp harmacogenomics. Inaddition, whent he importance ofpatient confidentiality int he future application ofpharmacogenomicsinm edicalcarei sconsidered, significant gaps exist. Newbusiness models have emergedthataimt ofocus on the integration andc onfidentiality ofd atasources. Thesei nclude models developed by FirstGenetic Trust 17 andthe ClinicalGenomicsbusiness unito fI BM.
Carryingout pharmacogenomicss tudies to deliverv alue
Withint he industrys etting, the ability to drivepharmacogenomicsinto the fabric ofthe business isdirectly dependent on the potentialt ohavea nimpacto nbusiness decisions. Thist hereforerequiresclosepartnershipw ithc olleaguesin discovery,d evelopment andc ommercialm arketingto work togethert os hapethe scientific direction ofresearch programmes. Giventhe challengesofthe pharmaceuticalindustry, includingthe high attrition which occursatevery stage throughout the pipeline, combined withthe longd evelopment timelines,e xcellent science alonei sn ot sufficient. Pharmacogenomicshastodriveimpactandinfluence decisions aimed atincreasingproductivity withindrugd iscovery and clinicaldevelopment.Ad iscussion focused on achievingsuch valuef ollows.
Choosingthe best target:A pplying humangeneticst oadd human relevance Thereexist significant unmetm edicaln eedso fpatients,a ndi t isn ow recognised thatcommon diseaseseffectingmorbidity andmortality haveasignificant genetic component. Considert he diseaseso fd iabetes,obesity andosteoarthritis, to nameb ut af ew. The degree ofg enetic contribution has beenestimated for thesed iseasesbased on twins tudiesand siblingriska nalysis. [18] [19] [20] [21] [22] [23] Similarly,rareg enemutations have providedi nsightinto complexbiologicalp rocessesinvolved inm orec ommon diseasephenotypes. For example, the importance ofc holesterylestert ransferp rotein( CETP)in influencinga nindividual'shigh-density lipoprotein( HDL) levels wasdemonstrated whenindividuals identifieda s possessinge xtremelevels ofH DL wereshownt oharbour a raremutation int heir CETP genea ndto lack CETP activity. 24, 25 Inanotherexample, subjects harbouring inactivatingmutations withint he Janus kinase3 gene( JAK3 ) express severecombined immunodeficiencysyndrome(SCID), providingmechanistic evidence thatJAK3inhibition was likely to effectimmunesuppression andpotentially servea s atherapy for transplant recipients. 26 Most importantly, the insightgained fromthe humangeneticsfindingsdescribed aboveh asl ed to newinvestigationaldrugsfor CETP inhibition andJAK3inhibition,which,upon entryinto the clinic, demonstratee fficacyconsistent withthe humangenetics data.
27,28
Whilenot traditionally defined asp harmacogenomics, humangenetic association studiesm ayp rovide animportant avenuefor establishingrelationships betweenhumangenesand diseasestatea ndthus influence the appropriateselection of therapeutic targets.Important newdiscoverieso fg enes associated withc omplexdiseasea ppeart oo ccur on aregular basisn ow,a sevidenced bydiseasea ssociations ofneuregulin andschizophrenia;
29 PDE4D andstroke; 30 and5 -lipoxgenase andatherosclerosis. 31 Thesestudieshavebeenstrengthened by additionals cientific datasupportingf unctionalr elationships betweent he genetic association andthe disease.
Pharmaceuticalcompanies,a sw ell asm any academic institutions,h aveb eencollectingD NA samplesw ith appropriatei nformed consent to investigatethe relationship betweengenetic variation andd iseasephenotypest obetter classifydisease.Through the collection ofc linicalp henotypes withlinkedD NA samples,the execution ofc linicalt rials providesano pportunity to investigatethe underlyingg enetic variation thatexists inp atients. Thisist ypified inastudy inw hich DNA fromp atientsw hop articipated inalipidloweringtrialdemonstrated astronga ssociation betweent he phenotypef or HDL levels andanovell ipaseg enef amily member,endotheliallipase( LIPG). 32 Whileassociation studies havehad mixed reviews inthe scientific community,oftendue to conflictingstudyr esults,c areful attention to studydesign canprovide the firstopportunity to add humandatato known andnovelgenes. Studydesignissuesinclude: careful selection ofa ppropriatestudys ubjects based on rigorous phenotypic criteria;u tility ofe xtremephenotypes; comprehensiveS NP selection which takesinto account linkage disequilibrium (LD)int he geneunders tudyt oensureadensity ofmarkers which capturethe LD pattern ofthe gene;s tatisticalm ethods allowingoneto assess how likely any result maybe dueto chance alone;and, finally,planned replication to provide added validation ofa ny genea ssociation. Thesea rec riticalt o the successful characterisation ofd iseaseriska lleles.
Whilec andidateg enestudieshaveb ecomec ommonplace int he literature, thesestudiesm ayo fteninvolveabiological hypothesisfor candidateg eneselection. The ability to interrogatethe genomeb ased solely on phenotypic criteria with no apriori biaso ngeneselection hasbeendramatically enha- 33 Recent reports evaluatingc ommon polymorphisms across candidate generegionss uggest that,i no rdert odetect . 80p ercent of all haplotypesinag ivenr egion usingh aplotype-tagging SNPs,itisnecessary to reach anr 2 of . 0.8. 34 Asthe HapMap projectp rogressesforwardwithd efiningthe linkage LD patternsint he humangenome, geneticists will havethe tools to evaluatethe extent ofLDwithinagivenregion andwithin ag ivenethnicity to selectt he optimalSNPst ogenotype whendesigningastudy. Thesed atawill provide valuable information aroundS NP selection,i rrespectiveofwhether the studydesignisfor awhole-genomea ssociation or candidateg ene-based studies.
Inanattemptt ov alidatethe haplotypetagginga pproach to identifygenetic associations,a sw ell ast oevaluatethe PerlegenSciencesarray-based chip-based genotypingplatform,7,283SNPss panning17.1 megabases( Mb)o fD NA wereg enotyped to identifyassociations withH DL levels. 36 SNPsassociated withthe 5 0 haploblock ofthe CETP gene werei dentifieda st he most significant association int he
Figure3. Exploitingwhole-genomea pproaches. Candidateg ene-based studieshaveb eenthe focus ofhumangenetic association studiesfor the past severaly ears. Ast he knowledge ofgenetic variation hasemerged andthe genotypingtechnologiest oinvestigate such variation havematured, our ability to carryout whole-genomea ssociation studiesappears poised to address fundamentalissues, such ast he association withc omplexdiseasesanddrugresponses.
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Review PERSPECTIVE dataset. 36 Readouts froms everalgenome-wide studiesare expected withint he next yearandwill provide furtherinsight into the potentialv alueofthesestudiest oidentifygenes involved incomplexdiseasephenotypes,i ncludingmetabolic syndromea ndd rugresponse.Thepublic HapMapp roject 7 andc ompaniesl ikeP erlegen,which recently announced its intention to provide its SNPmarkers into the public domain to furtheradvance the foundation for such experiments,will furtheraid thesewhole-genomea pproachesfor the scientific community.
Drugd iscovery andd evelopment: Understandingtargetv ariability
Early int he drugd iscovery phase, the assessment ofc omprehensivetargetv ariation achieved through generesequencingi nethnically diverseD NA panels providesdiscovery scientistsw ithi nformation thatiscriticalfor screendesign, functionalassessment ofvariant allelesanda nimalm odel design. Inp artnershipw ithc ompaniesl ikeG enaissance Pharmaceuticals,the present authorswill typically screenapanelof 92 DNA samplesw ithrepresentationsfromCaucasian,A sian, Hispanic andA frican-AmericanDNA samples,which allow the detection ofpolymorphismswithafrequencygreatert han 1p ercent. 37 For example, the CETP genevariation depicted inFigure4providesac omprehensiveunderstandingof the variation withint hisgenelocus. Inaddition,these comprehensiveS NP dataprovide the basisfor candidate gene-based studiest ointerrogatethe relationshipbetween putativetherapeutic targetgenesandh umandiseasephenotypes. 38 Thisknowledge oftargetv ariation cant henbe utilised for hypothesist estingi nearly clinicalp rogrammes, withparticularemphasisonp utativefunctionalv ariants which mayhaveb eendefined duringd iscovery studiesexploring functionalactivities. Thisisexemplified int he following discussion.
Drugd evelopment:T raditional pharmacogeneticsfor clinical decision making
Most,i fnot all,pharmaceuticalcompanieshavea ctively engaged int he area ofpharmacogenomicsw ithd iffering levels ofi nvestment,strategiesanda pplication. Itist he authors' belief,h owever,thatapplication ofthisdisciplinei s still inits infancy. Ye tt herea resomevery cleardemonstrationso fi mpactalreadyinp lace,withparticularemphasis on the oncologyarea, which ared escribed inm ored etailin the next section. 
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Figure4. Structureofthe cholesterylestert ransferprotein ( CETP)geneandpolymorphic markers. The CETP geneisl ocated on chromosome16 andc ontains anumberofpolymorphisms which havebeenidentified through denseresequencing.Thesepolymorphisms occur atdifferingf requenciesinvarious ethnic populations,a ss hown inthe accompanyingtable.Inthist able, the singlenucleotide polymorphism (SNP)m arkerisidentified andthe db SNP identifieralongwithothercommon namesfor the SNP andminor allelef requenciesfor Caucasians andA fricanAmericans (Af.Amer.). 38 Onecanalso lookto the area ofdrugmetabolism,the more classically defined area ofpharmacogenetics,a ndfi ndc lear demonstrations ofthe utility ofg enetic knowledge ofthe cytochromeP 450genefamily,a sw ell aso thergenesinvolved inthe pharmacokineticsofdrugdisposition. Thesegeneshave beenextensively studied, ande xampless uch ascytochrome P450CYP2D6,2C19 and2C9p rovide ac leardemonstration ofthe predictiveuseofg enotypei nclinicaldevelopment.For example, the useofg enotypingto predictp oorm etaboliser status for individuals deficient inCYP2D6enzymei su sed routinely whenevaluatingC YP2D6s ubstrates. 39, 40 Many excellent reviews haveb eenp ublished, providingd etailed summarieso fthe area ofd rugmetabolism andi ts importance for clinicaldevelopment. [41] [42] [43] [44] [45] Inthe early stagesofclinicaldevelopment,CYP2D6geno-typingi sr outinely employed for prospectiveenrolment or retrospectiveanalysisofsubjects,to rapidly establishindividual pharmacokinetic differencesfor thosecompoundssuspected to be metabolised via the CYP2D6pathway. 40 Additionally, drug-druginteraction studieswithexperimentaltherapiesand known CYP2D6substrates,such asparoxetine, canbenefitfrom the incorporation ofCYP2D6genotyping.
46,47 CYP2D6poor metabolisers maydemonstratealtered paroxetineexposure, which wouldremainunexplained inthe absence ofCYP2D6 genotyping, andthus incorporation ofthe genotypingdata removesthe potentialfor uncertainty inthoseindividuals who wouldbeexpected to demonstrateincreased exposuredueto the possession oftwonon-functionalallelesofCYP2D6.
Drugd evelopment:T ransitioning to proofofc oncept
The combined knowledge ofg enetic contributions to the underlyingd iseasestatea ndc omprehensived ataon target variation,providesn ewandvaluablei nsightw hich canbe applied inearly clinicals tudiesaimed atestablishingproofof concept for novelt herapeutic agents. Genetic biomarkers definingthe riskofd iseaseonsetand/or progression can potentially be used to selecto ptimalp atient populations in early clinicaldevelopment byt argetingag enetically defined diseaseriskpopulation relevant to the therapeutic intervention or the endpoint beingstudied.Thisisexemplified by recent dataf romdeCODE Genetics,i nw hich genetic variation withint he 5-lipoxygenasea ctivatingprotein (FLAP)genelocus wasassociated witha nincreased risk ofmyocardialinfarction int he Icelandic population.
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Functionalassessment ofi solated neutrophils fromindividuals carryingthe 'at-risk'four-SNPmarkerhaplotype demonstratesincreased production ofleukotrieneB 4, a major leukotrienei nt hisinflammatoryp athway. Thisu nique haplotypei dentifiesaspecific population inw hich to assess the potentialt herapeutic benefits ofaFLAP inhibitor,a nd deCODE Geneticshasinitiated clinicals tudiest ov alidate thisapproach, combiningg enetic enrichment withrelated biochemicalm easureso fd ruga ctivity andi nflammation to assess proofofc oncept.Shouldthiss tudyp rovesuccessful, the question will remainast ow hethert hism echanism will be beneficialint he genetically 'atr isk'FLAP haplotype individuals alone, or whethero therindividuals will also benefitfromt herapeutic intervention directed att hiss pecific mechanism. Thisisab oldnewapproach which has encouraged Merck to partnerw ithd eCODE Genetics,a nd will probably be watched carefully byo therp harmaceutical companies.
The utility andi mportance oftargetv ariation dataa nd knowledge aboutt he functionalr elevance ofthisv ariation to executepharmacogenomic studiesinearly development has also beenapplied int he development ofnovelt herapiesfor HIV.Genetic studiesfirstdemonstrated thatt he CCR5 receptor wasassociated withsusceptibility to HIV infection andthe progression to AIDS. 49 The CCR5 genehasbeenwell characterised, withparticularimportance placed on the delta 32 allele, asindividuals heterozygous for the allelee xhibits ignificant reduction inr eceptor numbers on the cell surface whilei ndividuals homozygous for the allelleh aveno functionalr eceptor present. Pharmaceuticalcompanieshave thereforerapidly moved CCR5 receptor antagonists from discovery into the clinic.Inearly clinicals tudieso faCCR5 antagonist,e xamination ofthe delta32 genotypeandreceptor density asm easured byfluorescence-activated cell sorting analysis,h ass hownt hatt he CCR5 delta32 wasn ot significantly associated witha ny safety andtoleration endpoints tested, nor withb aselinevirall oad.Preliminary investigation suggestsn oapparent relationshipbetweenCCR5 delta32, CCR5 expression andreceptor saturation inhealthyv olunteers.Futurestudiesw ill examinethe CCR5 genotypea nd antiretroviralactivity ast he compoundprogressest hrough clinicaldevelopment. 50 Utilisation inl ate-stage clinical development programmes andb eyond Itisoftendifficulttoascertainindividualpharmaceutical experience inlate-stage clinicaldevelopment,asmuch experience to datehasinvolved retrospectiveanalysisofclinical programmesandhasnot moved into trueprospectiveapplication. Inaddition,therestill exists asignificant rateoflate-stage attrition.Arecent publication fromthe US FoodandDrug Administration (FDA)provided someinsightinto the integration ofpharmacogenomicsinto clinicaldevelopment programmes,citingsome70 investigationalnewdrugapplications involvingpharmacogenomics; ofthese80percent involved cytochromeP450genotypingandwererelated to drugmetabolism. 51 Recent issuance ofthe draftguidance for Voluntary Genomic DataSubmissionsbythe FDAwill also promote Milos andS eymour Review PERSPECTIVE additionalregulatorydialogueandinformation sharingrelated to the application ofpharmacogenomics.
Rosesr ecently provided anexcellent examplewith Tranilast,aPhaseI II programmewhich wasu nsuccessful for restenosis,inwhich pharmacogenomicsdataweregenerated in realt imed uringthe PhaseI II development programme, demonstratingthatasmall percentage ofpatients developing hyperbilirubinaemia,d uringd rugtreatment contained a promoterv ariant int he UDG-glucuronosyltransferaseIgene ( UGT1 ); thisw asn ot seeninp lacebo-treated subjects.
52,53
ThisinitialTranilast workh asn ow beenextendedto model SNP scoringatadensity expected for whole-genomescans and to servea savalidation ofwhole-genomea nalysisfor identifyingg enomic regions associated withsafety events.Some76 haplotype-definingS NPs,spanninga2.7Mb region ofD NA includingthe UGT1A1 gene, wereexamined in1,054 patients whohad beent reated withT ranilast withno evident hyperbilirubinaemia, and147p atientsr eceivingtherapy whodid experience hyperbilirubinaemia.Thisanalysisdemonstrated an association ina150kilobaseregion thatincluded the UGT1A1 genelocus,which uponfurtherdensemappingconfirmed the association withthe UGT1A1 gene. 54, 55 Ta ble1describeso therexampleso fc urrently available drugst hathaveb eenexamined for genetic associationsw ith particulargenetic pathways or genemarkers.Thesereferences providea nearly window onto the typeso fstudiesw hich are exploringthe complexr elationshipbetweendrugresponse andg enetic heterogeneity inr elatively small numbers of individuals receivingsuch therapies. Theseh averelied on focused candidateg ene-based investigationsw ithlimited ability to interrogatethe entireg enome;however,i tisenvisioned thats everals uch genome-wide analysesw ill appearin the scientific community overt he comingyearo rt wo.
Utilisation ofpharmacogenomics ino ncologyt ohavea nimpact on patient care
Cancerisag enetic disease, bothi nt ermso fthe germline (inherited genome)asw ell ast he somatic genome, which is uniqueto the tumouritself.Whilemutationsingeness uch as BRCA1 and BRCA2 result inasignificant increasei n cancerr isk, thesetypeso fmutations represent only asmall percentage ofall tumours. 67 The vast majority ofcancers result froms omatic alterations withincells resultingi naselective growtha dvantage overt he well-controlled mechanisms of normalcell growth. [68] [69] [70] [71] Therea rec urrently technologies availablef or identifyinga ndstudyingthe molecularm echanisms definingvarious subtypeso fc ommon cancers andi ncorporatingthesed atai nto the drugd iscovery andd evelopment process. The characterisation andunderstandingofg enetic alterations drivingtumourigenesishasalreadyl ed to targeted oncologytherapieswithincreased benefittothesemolecularly Ta ble1. Selected exampleso fpharmacogenomicss tudiesinvestigatingcurrently availabletherapies. 72 Incells overexpressingthe Her-2neuproteinitw asdiscovered thattargeted reduction in the expression ofthe proteinr eturned the cancerous cells to a normals tate, leadingto the development ofamonoclonal antibodywhich attachest othe Her-2n eur eceptor to prevent the cell growthresponse.
73, 74 The overexpression ofthe Her-2 neu genei so bserved inapproximately 30 percent ofb reast cancers,anditisthis30percent ofpatientsthatappreciatethe optimalbenefitfromt hist argeted therapy. 75 Based on these data, current Herceptintherapy requireswomenwithadvanced breast cancert obe screened for Her-2n euo verexpression through fluorescence ins itu hybridisation or quantitative proteinm easures.
Gleevec,a pproved in2 001 for chronic myeloid leukaemia, treats asubseto fpatients whop ossess ag enetic rearrangement known ast he Philadelphia chromosome, inw hich atranslocation ofc hromosome9q34to 22q11 [t(9;22)( q34;q11)] occurs,resultingi nab reakpoint clusterr egion thatfuses twogenes, BCR andthe oncogene Abl ,resultingi nac onstitutively activeoncogenic productt hatp lays animportant roleincell growth.Atleast 90 percent ofpatientswithchronic myeloid leukaemia harbourt hist ranslocation,providing genetic evidence thatitp lays arolei ndiseaserisk. 76 Once again,g ainingaclearu nderstandingofthe molecularentity drivingthe disease, scientists atNovartisdeveloped Gleevec, aninhibitoro fB CR-ABL tyrosinek inase.AP haseI Istudy reported in2 002 showed major cytogenetic responsesin6 0 percent ofsubjects ð n ¼ 454Þ andc ompleteh aematological responsesin9 5percent ofsubjects whohad previously failed on treatment withi nterferon-alpha. 77 Genetic studieshavea lso beeninstrumentalinelucidating mechanisms ofresistance to cancert herapy.Severalr eports haveshownt hatt he causeofG leevec resistance inadvanced phased iseasei sdueto identifiedsomatic point mutations withint he ABL kinased omaininasubseto fpatients,which couldpossibly interferewithG leevec binding.
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Morerecently,the elucidation ofthe responseto the tyrosinek inasei nhibitorIressah asagainhighlighted the importance ofc haracterisingthe somatic alterations contributingto tumourigenesisandthe relationshipbetweent he mutations to increasethe confidence intargetmechanisms and drugresponse. 69 Inclinicaldevelopment,some10 percent of patientsw ithnon-small cell lungc ancerdemonstrated asignificant benefitw ithI ressa.WhenLynch etal .examined the EGFR genesequence -the targetfor Iressaa ction -i n tumourDNA isolated fromasubsetoftheseresponders,gainof-function mutations werei dentifiedi neighto ut ofnine responders,c ompared withzero out ofsevenn on-responders. 81 Paez etal .examined the EGFR geneinDNA obtained fromn on-small cell lungc ancert umours amplesandf ound similarm utationsino neout of61 tumour DNAsfromUSbased patients,whilei nJapanesepatientsthe incidence roseto 15out of5 8tumourDNAs,providingd atac orrelatingwith ano bserved increasei nr esponseratest oIressai nJapan. 69 Thesed atareinforce the importance ofc haracterising underlyingg enetic heterogeneity withinl arge tumourt ypes. Apriori knowledge ofspecificg enetic markers indicativeof drugresponsemayinfluence the designo fe arly proof-ofconcept clinicalt rials. Int he casementioned above, screening for those10 percent ofsubjects with EGFR mutationsfor enrolment wouldh avea ctually increased the powero fthe development studiess ubstantially byimprovingthe efficacy ratest hrough reducingi ntersubjectv ariability int umour heterogeneity.Studieshavea lso shownt he powero futilising expression-profilingpatternso fselected signatureg enesin definingprognostic criteria, asexemplified byarecent report definingprognostic criteria for metastatic diseasea cross multipletumourt ypes. 82 Thei ncorporation ofthesemolecular signaturesinto ad rugd iscovery andc linicaldevelopment programmemayinfluence many different phases,i ncluding the selection ofthe optimalt argetbased upont he rolei tp lays Milos andS eymour Review PERSPECTIVE inthe molecularaetiologyofthe tumour subtype;the potential to allowenrichment ofapatient population withmolecularly defined tumours,asexemplified aboveand, finally,enrichment ofthe patient population most atr iskf or diseaseprogression, to clearly test for druge ffect.
Conclusion
Asexemplified byt he oncologyexampleshighlighted in Ta ble2,pharmacogenomicsw ill havea nimpacto no ptimal targets election andwill increasee fficacyinclinicaldevelopment byt argetingpatient populations based on genetically defined diseasephenotypes. Itw ill also,ultimately,i nfluence patient carewhenitp rovidesac learbenefitt op hysicians' ability to deliverbetterm edicalcareto patients. Thisw ill requireacleardemonstration ofb enefito vers tandarda ssessments used inclinicalpractice,or whent he molecularbasiso f the diseasei ss ow ell understoodthatt he clearp athf or development requiresgenomic knowledge to advance drug development.Advancementsingenomic technologies,characterisation ofh umanp opulation genetic variation,e nhancements indiseasephenotypingmethodologies,a dvancesin informed consent processesandpatient confidentiality technologiesandthe integration ofmoleculars cience withthato f traditionalclinicalp ractice arepavingthe wayfor novel pharmacogenomic discoveriesaimed atcharacterisingd isease risk, contributingto novelt herapeuticsandprovidingc lues into the optimaltreatment regimenbased on acombination of clinically andg enetically defined disease.Whilewea restill in the early stagesofthisrevolution,significant opportunitiescan be envisaged for scientific innovation to shapethe futureof medicalcarea ndpatient healthf or many years to come.
